nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—kidney cancer—vaginal cancer	0.874	1	CtDrD
Pazopanib—MAP3K9—epithelium—vaginal cancer	0.00184	0.0145	CbGeAlD
Pazopanib—MAP3K9—mammalian vulva—vaginal cancer	0.0016	0.0126	CbGeAlD
Pazopanib—TAOK1—uterine cervix—vaginal cancer	0.00137	0.0108	CbGeAlD
Pazopanib—MAP3K9—female reproductive system—vaginal cancer	0.00137	0.0108	CbGeAlD
Pazopanib—ITK—endometrium—vaginal cancer	0.00136	0.0108	CbGeAlD
Pazopanib—ITK—mammalian vulva—vaginal cancer	0.00132	0.0104	CbGeAlD
Pazopanib—SH2B3—uterine cervix—vaginal cancer	0.00129	0.0102	CbGeAlD
Pazopanib—TAOK1—urethra—vaginal cancer	0.00126	0.00995	CbGeAlD
Pazopanib—MAP3K9—female gonad—vaginal cancer	0.00124	0.00983	CbGeAlD
Pazopanib—TAOK1—endometrium—vaginal cancer	0.00124	0.0098	CbGeAlD
Pazopanib—MAP3K9—vagina—vaginal cancer	0.00124	0.00978	CbGeAlD
Pazopanib—TAOK1—mammalian vulva—vaginal cancer	0.0012	0.00948	CbGeAlD
Pazopanib—SH2B3—urethra—vaginal cancer	0.00118	0.00937	CbGeAlD
Pazopanib—SH2B3—endometrium—vaginal cancer	0.00117	0.00922	CbGeAlD
Pazopanib—TAOK1—uterus—vaginal cancer	0.00114	0.00903	CbGeAlD
Pazopanib—SH2B3—mammalian vulva—vaginal cancer	0.00113	0.00892	CbGeAlD
Pazopanib—FGFR3—epithelium—vaginal cancer	0.00109	0.00861	CbGeAlD
Pazopanib—RIOK2—uterine cervix—vaginal cancer	0.00108	0.00853	CbGeAlD
Pazopanib—FGFR3—uterine cervix—vaginal cancer	0.00108	0.00853	CbGeAlD
Pazopanib—BMPR1B—epithelium—vaginal cancer	0.00108	0.00852	CbGeAlD
Pazopanib—SH2B3—uterus—vaginal cancer	0.00107	0.0085	CbGeAlD
Pazopanib—TAOK1—female reproductive system—vaginal cancer	0.00103	0.00811	CbGeAlD
Pazopanib—ITK—vagina—vaginal cancer	0.00102	0.00806	CbGeAlD
Pazopanib—RIOK2—urethra—vaginal cancer	0.000992	0.00784	CbGeAlD
Pazopanib—FGFR3—urethra—vaginal cancer	0.000992	0.00784	CbGeAlD
Pazopanib—RIOK2—endometrium—vaginal cancer	0.000976	0.00772	CbGeAlD
Pazopanib—STK36—uterine cervix—vaginal cancer	0.000969	0.00767	CbGeAlD
Pazopanib—PI4KB—uterine cervix—vaginal cancer	0.000955	0.00755	CbGeAlD
Pazopanib—AURKC—female reproductive system—vaginal cancer	0.000951	0.00752	CbGeAlD
Pazopanib—RIOK2—mammalian vulva—vaginal cancer	0.000944	0.00747	CbGeAlD
Pazopanib—FGFR3—mammalian vulva—vaginal cancer	0.000944	0.00747	CbGeAlD
Pazopanib—LIMK2—uterine cervix—vaginal cancer	0.000937	0.00741	CbGeAlD
Pazopanib—TAOK1—female gonad—vaginal cancer	0.000934	0.00738	CbGeAlD
Pazopanib—TAOK1—vagina—vaginal cancer	0.000928	0.00734	CbGeAlD
Pazopanib—STK36—urethra—vaginal cancer	0.000891	0.00705	CbGeAlD
Pazopanib—BMPR1B—uterus—vaginal cancer	0.00089	0.00704	CbGeAlD
Pazopanib—SH2B3—female gonad—vaginal cancer	0.000879	0.00695	CbGeAlD
Pazopanib—PI4KB—urethra—vaginal cancer	0.000877	0.00694	CbGeAlD
Pazopanib—STK36—endometrium—vaginal cancer	0.000877	0.00693	CbGeAlD
Pazopanib—SH2B3—vagina—vaginal cancer	0.000874	0.00691	CbGeAlD
Pazopanib—PLK4—female reproductive system—vaginal cancer	0.00087	0.00688	CbGeAlD
Pazopanib—PI4KB—endometrium—vaginal cancer	0.000863	0.00683	CbGeAlD
Pazopanib—FLT4—epithelium—vaginal cancer	0.000849	0.00672	CbGeAlD
Pazopanib—STK36—mammalian vulva—vaginal cancer	0.000848	0.00671	CbGeAlD
Pazopanib—LIMK2—endometrium—vaginal cancer	0.000848	0.0067	CbGeAlD
Pazopanib—PIP4K2C—uterine cervix—vaginal cancer	0.000838	0.00662	CbGeAlD
Pazopanib—PI4KB—mammalian vulva—vaginal cancer	0.000835	0.0066	CbGeAlD
Pazopanib—FGFR1—uterine cervix—vaginal cancer	0.000831	0.00657	CbGeAlD
Pazopanib—STK16—female reproductive system—vaginal cancer	0.000821	0.0065	CbGeAlD
Pazopanib—LIMK2—mammalian vulva—vaginal cancer	0.00082	0.00648	CbGeAlD
Pazopanib—FGFR3—female reproductive system—vaginal cancer	0.000809	0.00639	CbGeAlD
Pazopanib—RIOK2—female reproductive system—vaginal cancer	0.000809	0.00639	CbGeAlD
Pazopanib—MAP3K19—female reproductive system—vaginal cancer	0.0008	0.00633	CbGeAlD
Pazopanib—BMPR1B—female reproductive system—vaginal cancer	0.0008	0.00633	CbGeAlD
Pazopanib—PI4KB—uterus—vaginal cancer	0.000796	0.00629	CbGeAlD
Pazopanib—MAP3K2—uterine cervix—vaginal cancer	0.000794	0.00628	CbGeAlD
Pazopanib—LIMK2—uterus—vaginal cancer	0.000781	0.00618	CbGeAlD
Pazopanib—PIP4K2C—urethra—vaginal cancer	0.00077	0.00609	CbGeAlD
Pazopanib—FGFR1—urethra—vaginal cancer	0.000764	0.00604	CbGeAlD
Pazopanib—PIP4K2C—endometrium—vaginal cancer	0.000758	0.00599	CbGeAlD
Pazopanib—FGF1—epithelium—vaginal cancer	0.000755	0.00597	CbGeAlD
Pazopanib—STK16—female gonad—vaginal cancer	0.000747	0.00591	CbGeAlD
Pazopanib—LCK—uterine cervix—vaginal cancer	0.000744	0.00588	CbGeAlD
Pazopanib—STK16—vagina—vaginal cancer	0.000743	0.00587	CbGeAlD
Pazopanib—RIOK2—female gonad—vaginal cancer	0.000736	0.00582	CbGeAlD
Pazopanib—PIP4K2C—mammalian vulva—vaginal cancer	0.000733	0.0058	CbGeAlD
Pazopanib—RIOK2—vagina—vaginal cancer	0.000731	0.00578	CbGeAlD
Pazopanib—BMPR1B—female gonad—vaginal cancer	0.000728	0.00576	CbGeAlD
Pazopanib—FGFR1—mammalian vulva—vaginal cancer	0.000727	0.00575	CbGeAlD
Pazopanib—STK36—female reproductive system—vaginal cancer	0.000726	0.00574	CbGeAlD
Pazopanib—PI4KB—female reproductive system—vaginal cancer	0.000715	0.00566	CbGeAlD
Pazopanib—FGFR2—epithelium—vaginal cancer	0.000713	0.00563	CbGeAlD
Pazopanib—FGFR2—uterine cervix—vaginal cancer	0.000706	0.00559	CbGeAlD
Pazopanib—LIMK2—female reproductive system—vaginal cancer	0.000702	0.00555	CbGeAlD
Pazopanib—FGFR1—uterus—vaginal cancer	0.000692	0.00548	CbGeAlD
Pazopanib—LCK—urethra—vaginal cancer	0.000683	0.0054	CbGeAlD
Pazopanib—MAP3K2—uterus—vaginal cancer	0.000662	0.00523	CbGeAlD
Pazopanib—STK36—female gonad—vaginal cancer	0.000661	0.00523	CbGeAlD
Pazopanib—FLT1—epithelium—vaginal cancer	0.00066	0.00522	CbGeAlD
Pazopanib—STK36—vagina—vaginal cancer	0.000657	0.00519	CbGeAlD
Pazopanib—FLT1—uterine cervix—vaginal cancer	0.000655	0.00518	CbGeAlD
Pazopanib—PI4KB—female gonad—vaginal cancer	0.000651	0.00515	CbGeAlD
Pazopanib—LCK—mammalian vulva—vaginal cancer	0.000651	0.00514	CbGeAlD
Pazopanib—EPHB6—uterine cervix—vaginal cancer	0.000647	0.00512	CbGeAlD
Pazopanib—PI4KB—vagina—vaginal cancer	0.000647	0.00512	CbGeAlD
Pazopanib—LIMK2—female gonad—vaginal cancer	0.000639	0.00505	CbGeAlD
Pazopanib—LIMK2—vagina—vaginal cancer	0.000635	0.00502	CbGeAlD
Pazopanib—FLT4—female reproductive system—vaginal cancer	0.000631	0.00499	CbGeAlD
Pazopanib—PIP4K2C—female reproductive system—vaginal cancer	0.000628	0.00496	CbGeAlD
Pazopanib—STK10—uterine cervix—vaginal cancer	0.00062	0.0049	CbGeAlD
Pazopanib—LCK—uterus—vaginal cancer	0.00062	0.0049	CbGeAlD
Pazopanib—TAOK3—uterine cervix—vaginal cancer	0.000618	0.00488	CbGeAlD
Pazopanib—FLT1—urethra—vaginal cancer	0.000602	0.00476	CbGeAlD
Pazopanib—MAP3K2—female reproductive system—vaginal cancer	0.000595	0.0047	CbGeAlD
Pazopanib—EPHB6—urethra—vaginal cancer	0.000595	0.0047	CbGeAlD
Pazopanib—FLT1—endometrium—vaginal cancer	0.000592	0.00468	CbGeAlD
Pazopanib—FGFR2—uterus—vaginal cancer	0.000589	0.00466	CbGeAlD
Pazopanib—EPHB6—endometrium—vaginal cancer	0.000585	0.00463	CbGeAlD
Pazopanib—FLT4—female gonad—vaginal cancer	0.000574	0.00454	CbGeAlD
Pazopanib—FLT1—mammalian vulva—vaginal cancer	0.000573	0.00453	CbGeAlD
Pazopanib—PIP4K2C—female gonad—vaginal cancer	0.000571	0.00452	CbGeAlD
Pazopanib—PIP4K2C—vagina—vaginal cancer	0.000568	0.00449	CbGeAlD
Pazopanib—TAOK3—urethra—vaginal cancer	0.000567	0.00449	CbGeAlD
Pazopanib—FGFR1—female gonad—vaginal cancer	0.000566	0.00448	CbGeAlD
Pazopanib—EPHB6—mammalian vulva—vaginal cancer	0.000566	0.00448	CbGeAlD
Pazopanib—FGFR1—vagina—vaginal cancer	0.000563	0.00445	CbGeAlD
Pazopanib—FGF1—female reproductive system—vaginal cancer	0.000561	0.00443	CbGeAlD
Pazopanib—TAOK3—endometrium—vaginal cancer	0.000559	0.00442	CbGeAlD
Pazopanib—KDR—epithelium—vaginal cancer	0.000558	0.00442	CbGeAlD
Pazopanib—MAP2K5—uterine cervix—vaginal cancer	0.000554	0.00438	CbGeAlD
Pazopanib—KDR—uterine cervix—vaginal cancer	0.000554	0.00438	CbGeAlD
Pazopanib—FLT1—uterus—vaginal cancer	0.000546	0.00432	CbGeAlD
Pazopanib—STK10—mammalian vulva—vaginal cancer	0.000542	0.00429	CbGeAlD
Pazopanib—MAP3K2—female gonad—vaginal cancer	0.000541	0.00428	CbGeAlD
Pazopanib—TAOK3—mammalian vulva—vaginal cancer	0.00054	0.00427	CbGeAlD
Pazopanib—CSF1R—uterine cervix—vaginal cancer	0.00054	0.00427	CbGeAlD
Pazopanib—FGFR2—female reproductive system—vaginal cancer	0.000529	0.00419	CbGeAlD
Pazopanib—STK10—uterus—vaginal cancer	0.000517	0.00409	CbGeAlD
Pazopanib—TAOK3—uterus—vaginal cancer	0.000515	0.00407	CbGeAlD
Pazopanib—PDGFRA—uterus—vaginal cancer	0.000511	0.00404	CbGeAlD
Pazopanib—FGF1—female gonad—vaginal cancer	0.00051	0.00403	CbGeAlD
Pazopanib—KDR—urethra—vaginal cancer	0.000509	0.00402	CbGeAlD
Pazopanib—MAP2K5—urethra—vaginal cancer	0.000509	0.00402	CbGeAlD
Pazopanib—LCK—female gonad—vaginal cancer	0.000507	0.00401	CbGeAlD
Pazopanib—LCK—vagina—vaginal cancer	0.000504	0.00398	CbGeAlD
Pazopanib—KDR—endometrium—vaginal cancer	0.000501	0.00396	CbGeAlD
Pazopanib—MAP2K5—endometrium—vaginal cancer	0.000501	0.00396	CbGeAlD
Pazopanib—CSF1R—urethra—vaginal cancer	0.000496	0.00393	CbGeAlD
Pazopanib—KIT—epithelium—vaginal cancer	0.000495	0.00391	CbGeAlD
Pazopanib—FLT1—female reproductive system—vaginal cancer	0.000491	0.00388	CbGeAlD
Pazopanib—KIT—uterine cervix—vaginal cancer	0.000491	0.00388	CbGeAlD
Pazopanib—CSF1R—endometrium—vaginal cancer	0.000489	0.00386	CbGeAlD
Pazopanib—KDR—mammalian vulva—vaginal cancer	0.000484	0.00383	CbGeAlD
Pazopanib—MAP2K5—mammalian vulva—vaginal cancer	0.000484	0.00383	CbGeAlD
Pazopanib—PDGFRB—epithelium—vaginal cancer	0.000483	0.00382	CbGeAlD
Pazopanib—FGFR2—female gonad—vaginal cancer	0.000482	0.00381	CbGeAlD
Pazopanib—PDGFRB—uterine cervix—vaginal cancer	0.000479	0.00379	CbGeAlD
Pazopanib—CSF1R—mammalian vulva—vaginal cancer	0.000473	0.00374	CbGeAlD
Pazopanib—STK10—female reproductive system—vaginal cancer	0.000464	0.00367	CbGeAlD
Pazopanib—TAOK3—female reproductive system—vaginal cancer	0.000463	0.00366	CbGeAlD
Pazopanib—KDR—uterus—vaginal cancer	0.000461	0.00365	CbGeAlD
Pazopanib—PDGFRA—female reproductive system—vaginal cancer	0.00046	0.00364	CbGeAlD
Pazopanib—KIT—urethra—vaginal cancer	0.000451	0.00357	CbGeAlD
Pazopanib—CSF1R—uterus—vaginal cancer	0.00045	0.00356	CbGeAlD
Pazopanib—FLT1—female gonad—vaginal cancer	0.000446	0.00353	CbGeAlD
Pazopanib—FLT1—vagina—vaginal cancer	0.000444	0.00351	CbGeAlD
Pazopanib—KIT—endometrium—vaginal cancer	0.000444	0.00351	CbGeAlD
Pazopanib—EPHB6—female gonad—vaginal cancer	0.000441	0.00349	CbGeAlD
Pazopanib—PDGFRB—urethra—vaginal cancer	0.00044	0.00348	CbGeAlD
Pazopanib—EPHB6—vagina—vaginal cancer	0.000439	0.00347	CbGeAlD
Pazopanib—PDGFRB—endometrium—vaginal cancer	0.000433	0.00343	CbGeAlD
Pazopanib—KIT—mammalian vulva—vaginal cancer	0.000429	0.00339	CbGeAlD
Pazopanib—STK10—female gonad—vaginal cancer	0.000423	0.00334	CbGeAlD
Pazopanib—TAOK3—female gonad—vaginal cancer	0.000421	0.00333	CbGeAlD
Pazopanib—STK10—vagina—vaginal cancer	0.00042	0.00332	CbGeAlD
Pazopanib—PDGFRB—mammalian vulva—vaginal cancer	0.000419	0.00331	CbGeAlD
Pazopanib—TAOK3—vagina—vaginal cancer	0.000418	0.00331	CbGeAlD
Pazopanib—PDGFRA—female gonad—vaginal cancer	0.000418	0.00331	CbGeAlD
Pazopanib—PDGFRA—vagina—vaginal cancer	0.000416	0.00329	CbGeAlD
Pazopanib—KDR—female reproductive system—vaginal cancer	0.000415	0.00328	CbGeAlD
Pazopanib—MAP2K5—female reproductive system—vaginal cancer	0.000415	0.00328	CbGeAlD
Pazopanib—KIT—uterus—vaginal cancer	0.000409	0.00323	CbGeAlD
Pazopanib—CSF1R—female reproductive system—vaginal cancer	0.000405	0.0032	CbGeAlD
Pazopanib—PDGFRB—uterus—vaginal cancer	0.000399	0.00316	CbGeAlD
Pazopanib—KDR—female gonad—vaginal cancer	0.000377	0.00298	CbGeAlD
Pazopanib—MAP2K5—female gonad—vaginal cancer	0.000377	0.00298	CbGeAlD
Pazopanib—MAP2K5—vagina—vaginal cancer	0.000375	0.00297	CbGeAlD
Pazopanib—KDR—vagina—vaginal cancer	0.000375	0.00297	CbGeAlD
Pazopanib—CSF1R—female gonad—vaginal cancer	0.000368	0.00291	CbGeAlD
Pazopanib—KIT—female reproductive system—vaginal cancer	0.000368	0.00291	CbGeAlD
Pazopanib—CSF1R—vagina—vaginal cancer	0.000366	0.00289	CbGeAlD
Pazopanib—SLCO1B1—female reproductive system—vaginal cancer	0.000365	0.00289	CbGeAlD
Pazopanib—PDGFRB—female reproductive system—vaginal cancer	0.000359	0.00284	CbGeAlD
Pazopanib—KIT—female gonad—vaginal cancer	0.000334	0.00264	CbGeAlD
Pazopanib—KIT—vagina—vaginal cancer	0.000332	0.00263	CbGeAlD
Pazopanib—PDGFRB—female gonad—vaginal cancer	0.000327	0.00258	CbGeAlD
Pazopanib—PDGFRB—vagina—vaginal cancer	0.000325	0.00257	CbGeAlD
Pazopanib—ABCG2—uterine cervix—vaginal cancer	0.000269	0.00213	CbGeAlD
Pazopanib—CYP2C8—endometrium—vaginal cancer	0.000251	0.00198	CbGeAlD
Pazopanib—ABCG2—urethra—vaginal cancer	0.000247	0.00196	CbGeAlD
Pazopanib—ABCG2—endometrium—vaginal cancer	0.000244	0.00193	CbGeAlD
Pazopanib—ABCG2—mammalian vulva—vaginal cancer	0.000236	0.00186	CbGeAlD
Pazopanib—ABCG2—uterus—vaginal cancer	0.000224	0.00177	CbGeAlD
Pazopanib—CYP2C8—female reproductive system—vaginal cancer	0.000208	0.00164	CbGeAlD
Pazopanib—CYP2C8—vagina—vaginal cancer	0.000188	0.00148	CbGeAlD
Pazopanib—ABCG2—female gonad—vaginal cancer	0.000184	0.00145	CbGeAlD
Pazopanib—ABCG2—vagina—vaginal cancer	0.000182	0.00144	CbGeAlD
Pazopanib—CYP3A4—female reproductive system—vaginal cancer	0.000141	0.00111	CbGeAlD
Pazopanib—CYP2D6—female reproductive system—vaginal cancer	0.000138	0.00109	CbGeAlD
Pazopanib—ABCB1—epithelium—vaginal cancer	0.000134	0.00106	CbGeAlD
Pazopanib—ABCB1—uterine cervix—vaginal cancer	0.000133	0.00105	CbGeAlD
Pazopanib—CYP2D6—female gonad—vaginal cancer	0.000126	0.000995	CbGeAlD
Pazopanib—ABCB1—urethra—vaginal cancer	0.000122	0.000965	CbGeAlD
Pazopanib—ABCB1—endometrium—vaginal cancer	0.00012	0.00095	CbGeAlD
Pazopanib—ABCB1—mammalian vulva—vaginal cancer	0.000116	0.000919	CbGeAlD
Pazopanib—ABCB1—uterus—vaginal cancer	0.000111	0.000875	CbGeAlD
Pazopanib—ABCB1—female reproductive system—vaginal cancer	9.95e-05	0.000787	CbGeAlD
Pazopanib—ABCB1—female gonad—vaginal cancer	9.05e-05	0.000716	CbGeAlD
Pazopanib—ABCB1—vagina—vaginal cancer	9e-05	0.000712	CbGeAlD
